Elvis Paćelat outlines some lessons from big pharma as medical device manufacturers succumb to new reporting obligations.
Elvis Pacelat
Advertisement
Elvis Pacelat, is VP of Compliance Solutions at AMPLEXOR Life Scienceswww.amplexor.com
Articles by Elvis Pacelat
However conservative and heavily regulated the drugs business, it too must transform itself to exploit digital opportunities - if only to ward off disruption, says Elvis Paćelat.
Advertisement
Latest Updated Articles
Pharma Must Embrace Digital TransformationNovember 29th 2016
The Great Life Sciences Regulatory RedressApril 24th 2019
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5